Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer

Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer

Abstract Background Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to neoadjuvant chemoradiation (CRT) alone. They further indicate that the o...

Full description

Bibliographic Details
Main Authors: Janet A. Alvarez, Qian Shi, Arvind Dasari, Julio Garcia-Aguilar, Hanna Sanoff, Thomas J. George, Theodore Hong, Greg Yothers, Philip Philip, Garth Nelson, Tareq Al Baghdadi, Olatunji B. Alese, Wini Zambare, Dana Omer, Floris S. Verheij, Aron Bercz, Min Jung Kim, James Buckley, Hannah Williams, Manju George, Reese Garcia, Phuong Gallagher, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Jamie Crawley, Ardaman Shergill, Natally Horvat, Paul B. Romesser, William Hall, J. Joshua Smith
Format: Article
Language:English
Published: BMC 2024-07-01
Series:BMC Cancer
Subjects:
Clinical complete response
Locally advanced rectal cancer
Organ preservation
Total neoadjuvant therapy
Watch and wait/active surveillance
Online Access:https://doi.org/10.1186/s12885-024-12529-7

Internet

https://doi.org/10.1186/s12885-024-12529-7

Similar Items